 I. To compare the difference in the biochemical progression-free survival rate bPFS at 2-years between immediate androgen deprivation therapy ADT for nine months in high risk prostate cancer patients following radical prostatectomy and a similar high risk patient population followed without initiation of immediate ADT treatment. 